Coming Off Wegovy and Ozempic: What to Expect When You Stop Semaglutide

Summary

Stopping semaglutide should be understood as a biology handoff. Semaglutide has an elimination half-life of about one week, and it can remain in circulation for about 5 to 7 weeks after the last 2.4 mg Wegovy dose and about 5 weeks after the last Ozempic dose. [1] That long tail is why many people feel okay at first, then notice hunger and weight rebound ramping up later.

The most cited discontinuation data point is real: in the STEP 1 trial extension, one year after stopping semaglutide 2.4 mg, participants regained about two thirds of their prior weight loss, and cardiometabolic improvements drifted back toward baseline. [2] A separate withdrawal trial, STEP 4, showed the same directional truth more cleanly: those who continued semaglutide kept losing weight, while those switched to placebo regained weight during the randomised phase. [3]

A 2026 systematic review in The BMJ puts rebound into a broader frame: after stopping weight management medications, average regain was estimated at roughly 0.4 kg per month, with faster regain after newer incretin drugs, and cardiometabolic markers projected to return toward baseline within roughly 1.4 years after stopping. The review also found no evidence that more intense behavioural support during treatment meaningfully changed the rate of regain after stopping. [4]

This means that "just build habits while you're on it" is not the reliable protection most clinics imply it is.

What stopping semaglutide actually means

Semaglutide is designed to be sticky. Both Wegovy and Ozempic have an elimination half-life of roughly one week and a prolonged washout of 5 to 7 weeks after the last Wegovy dose, and about 5 weeks after the last Ozempic dose. [1]

That pharmacology creates a predictable psychological trap: you stop injections, nothing dramatic happens immediately, you assume you are safe, and then appetite and food noise surge later, right when motivation is lowest.

What the evidence says happens after you stop

STEP 1 extension: the regain story most people quote

In the STEP 1 trial, semaglutide 2.4 mg plus lifestyle intervention produced mean weight change of -14.9% versus -2.4% with placebo at 68 weeks. [10] The STEP 1 extension then asked what happens when you remove the drug. Over the year after withdrawal, participants regained about two thirds of prior weight loss, and improvements in blood pressure, lipids, and glycaemic markers tended to revert toward baseline. [2]

What most summaries miss is the design nuance: active lifestyle support was also removed during the off-treatment year. [2] That is more "real life" than best case. It does not mean lifestyle is irrelevant, but it does mean the extension reflects what happens when pharmacology ends and the scaffolding fades together.

STEP 4: a cleaner continue versus stop test

STEP 4 randomised people to continue semaglutide or switch to placebo after a 20-week run-in. From week 20 to week 68, those continuing semaglutide changed -7.9% versus +6.9% for those switched to placebo. [3] Regain happened despite ongoing lifestyle intervention in both groups.

The bigger picture: regain is not just a semaglutide story

A 2026 systematic review and meta-analysis in The BMJ pooled 37 studies and 9,341 participants. It estimated average regain of roughly 0.4 kg per month, with projected return to baseline weight by about 1.7 years after stopping. For newer, more effective incretins, modelled regain rates were higher, up to roughly 0.8 kg per month, with return to baseline projected around 1.5 to 1.6 years. [4]

The same analysis modelled cardiometabolic markers trending back toward baseline, with projected return close to baseline by about 1.4 years after stopping. [4] Regain is not merely disappointing. It carries metabolic consequences.

Why rebound happens

Metabolic adaptation

Long-term weight maintenance is difficult partly because energy expenditure often drops more than expected after weight loss, a phenomenon known as adaptive thermogenesis, and that reduced expenditure can persist while weight is suppressed. When semaglutide's appetite suppression fades, appetite can rise into a metabolism that is still running efficiently. [14]

Lean mass loss and sarcopenic regain

In the STEP 1 DEXA sub-study, semaglutide reduced fat mass substantially but total lean body mass also decreased. [7] If you stop semaglutide after losing weight without explicitly rebuilding or defending muscle, regain can occur in a worse ratio, more fat relative to lean, which makes appetite regulation and long-term maintenance harder. Resistance training and adequate protein are not optional extras on the off-ramp. They are the mechanism.

Alcohol rebound

There is now randomised trial evidence that semaglutide can reduce alcohol craving and intake in some people. Stopping can quietly reintroduce both calories and reward-seeking without the patient making a conscious decision to drink more. This is an underappreciated contributor to regain that rarely appears in mainstream stopping guides. [7]

Reward-salience rebound

Food can feel more compelling after stopping, not just more present. The central appetite and reward modulation that semaglutide provides is not simply a matter of slowing gastric emptying. A dedicated trial in adults with obesity found no evidence of delayed gastric emptying at week 20 for semaglutide 2.4 mg, while still showing reduced appetite, reduced cravings, and lower energy intake. [19] Much of what patients experience as GLP-1 fullness is likely central nervous system modulation of appetite and reward, not just a slow stomach.

What most off-ramp guides miss

The problem is often not that you lack discipline. It is that you are removing a powerful appetite and reward lever and expecting willpower to impersonate pharmacology. That framing matters because it changes what you prepare for.

The under-discussed angles that actually change the off-ramp:

• Alcohol drift. Semaglutide may reduce alcohol intake. Stopping can quietly reintroduce calories and reward-seeking patterns.
• Sarcopenic regain. If lean mass was lost during treatment, regain can skew toward fat unless muscle is actively defended.
• Limits of behavioural support. The BMJ meta-analysis found no evidence that more intense behavioural support during treatment meaningfully changed regain rate after stopping. Generic lifestyle advice often does not slow rebound. [4]
• Monitoring tactics. Simple, consistent tracking of weight trend, waist, and strength can catch rebound early enough to act on it.

The off-ramp plan

Before you stop

Set up monitoring in advance. Decide what success means for the next eight weeks. A weight trend, waist measurement, and one simple strength metric you can repeat consistently. If you have type 2 diabetes, agree a glucose monitoring plan with your clinician before stopping, including home readings, medication adjustments, and clear thresholds for when to seek review.

Weeks 1 to 2: the quiet decline

In weeks 1 to 2, you may notice very little. The drug is still clearing, not truly absent. [1] This period is when people become falsely reassured. The minimum effective response: weigh three to four times per week to detect trends early; anchor every meal around a clear protein source; complete two full-body resistance sessions per week as a minimum floor.

Weeks 3 to 6: appetite returns, regain risk rises

Tirzepatide exposure is now much lower and may be close to negligible by the end of this period. [1] Hunger and cravings may feel more present. Food cues may become louder. A small upward drift in weight may begin. The key is to act on trend rather than emotion. If weight trends upward for two consecutive weeks, tighten structure: pre-planned meals, less trigger food at home, protein earlier in the day, fewer liquid calories. Add a third short resistance session or more sets. If you have diabetes and readings are climbing, involve your clinician early.

Beyond 6 weeks: new baseline

You are increasingly living without the pharmacological buffer. [1] Strength becomes the north star because it relates to function and helps defend against metabolic drift. If regain becomes substantial, options may need to be reconsidered, including restarting treatment. This should be understood as a clinical decision, not a personal failure. NICE obesity guidance is clear about who qualifies and under what circumstances.

When to involve your clinician

Before stopping if you have type 2 diabetes; at the first sign of rapid appetite return or rising weight trend; if stopping because of adverse effects, particularly persistent or severe gastrointestinal symptoms; if peri-operative planning is relevant; or if significant distress, binge patterns, or loss-of-control eating emerge.

When to seek urgent help

Severe or persistent abdominal pain especially with vomiting; signs of dehydration; if you have diabetes and experience very high glucose, ketone concerns, or escalating symptoms of hyperglycaemia. Do not treat obvious warning signs as something to watch and wait.

Bottom line

Stopping semaglutide without a plan is one of the most predictable clinical mistakes in this space. The evidence is clear and consistent: appetite returns, weight follows, and cardiometabolic gains reverse. The solution is not more motivation. It is a clinical plan built before you stop, with monitoring from the first week, resistance training as a structural component, and a defined point at which you involve your clinician if the trajectory is not holding.

If you want a proper clinical plan for your semaglutide off-ramp, that is exactly what a GLP-1 Exit Strategy Review is designed to provide.